Meriofert

Follicle-Stimulating Hormone; Luteinising Hormone, the active ingredient in Meriofert, is a gonadotropin presented as an injectable solution for subcutaneous use. It is used to stimulate ovarian follicular development in women with infertility related to anovulation or hypogonadotropic hypogonadism.

GNH USA supplies Meriofert as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Meriofert acts on the reproductive hormone axis to support follicular growth and ovulation in several infertility contexts.

Infertility due to anovulation: induces ovulation by stimulating follicle development. Hypogonadotropic hypogonadism: replaces deficient gonadotropins to restore ovarian function. Assisted reproductive technology (ART) protocols: provides controlled ovarian stimulation for egg retrieval.

Meriofert may cause a range of adverse reactions, from mild to severe. Monitoring and prompt reporting are essential.

Common Side Effects: - Injection site pain or erythema. - Mild abdominal discomfort or bloating. - Nausea or mild headache. - Transient mild ovarian hyperstimulation syndrome. - Mood changes or fatigue.

Serious or Rare Side Effects: - Severe ovarian hyperstimulation syndrome with rapid weight gain and fluid accumulation. - Allergic reactions including anaphylaxis. - Thromboembolic events such as deep vein thrombosis. - Multiple pregnancy resulting from excessive follicular response. - Ectopic pregnancy.

Prior to initiating Meriofert, clinicians should assess patient suitability and monitor response closely.

Monitor ovarian response: use serial ultrasound and estradiol measurements. Assess contraindications: avoid in active ovarian cysts or uncontrolled thyroid disease. Avoid use in pregnancy: the drug is not indicated for pregnant women. Consider risk of multiple pregnancy: limit the number of developing follicles. Adjust dose in renal or hepatic impairment: follow prescriber guidance. Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Meriofert may interact with other medications that influence hormonal balance or coagulation.

Major Interactions (Avoid): - GnRH agonists: can amplify response and increase risk of severe ovarian hyperstimulation. - Estrogen‑containing contraceptives: may antagonize the intended ovulatory effect. - High‑dose corticosteroids: may alter hormone metabolism and reduce efficacy.

Moderate Interactions (Monitor Closely): - Anticoagulants: monitor for bleeding if ovarian cyst rupture occurs. - Thyroid hormone therapy: may affect overall hormonal response. - Concurrent use of other gonadotropins: avoid overlapping therapy to prevent excessive stimulation.